NOVA™ is a comprehensive screening test to determine a baby’s risk of 50 inherited disorders, as well as providing personalized genetic information on the likely response to 20 paediatric drugs. Utilizing Next-Generation Sequencing technology and with access to  industry leading genetics bioinformatics software from BGI, NOVA™ offers the most comprehensive and accurate newborn screening test on the market with a positive predictive value (PPV) of >99%. To find out more about the test, please visit www.novatest.sk.